AI and Cancer Research ── Liver ── 2026-11-19
Liver cancer: treatment, trials and AI
- Abstract
Background/Objectives: Hepatic arterial infusion chemotherapy (HAIC) is increasingly combined with tyrosine kinase inhibitors, immune checkpoint inhibitors or transarterial chemoembolisation, yet radiomics models seldom distinguish HAIC alone from HAIC within a multi-agent regimen. We reviewed handcrafted or semi-automated radiomics models in HAIC, stratified by regimen.
Methods: Following PRISMA 2020 (PROSPERO CRD420261487449), MEDLINE, Embase and Web of Science were searched to 6 November 2026 for English-language studies combining radiomic feature extraction with a machine-learning classifier to predict response, survival or treatment selection; end-to-end deep-learning studies were excluded. Studies were classified as monotherapy, combination regimen or mixed, appraised with the Radiomics Quality Score, PROBAST+AI and METRICS, and synthesised narratively.
Results: Eleven studies (2032 patients) were included: five monotherapy, four combination-regimen and two mixed or non-separable-regimen studies. Validation, test or bootstrap AUCs were 0.75–0.90 for monotherapy and 0.86–0.97 for combination-regimen studies; the highest values (0.99) were training-set estimates. Excluding three studies with uncertain regimen widened the gap. Only two had external validation, none shared data or code, and most had high or unclear risk of bias.
Conclusions: Handcrafted radiomics models show high but methodologically immature discrimination. Higher combination-regimen AUCs are confounded by tumour type, cohort and pipeline and do not demonstrate a HAIC-specific effect.
Funding: none.
Journal IF-equivalent: 6.1 (OpenAlex 2-year mean citedness, value as of 2026-11-07, retrieved 2026-11-08; not the official Clarivate IF)Reference: Tan YZ, Temperley HC, O’Sullivan NJ, Gallagher D, Gillham C, Harrold E, et al. Handcrafted and Semi-Automated Radiomics Models for Hepatic Arterial Infusion Chemotherapy: A Systematic Review Stratified by Monotherapy and Combination Regimens. Cancers. 2026 Nov 15;18(22):3655. doi:10.3390/cancers18223655.Checked: Abstract only - Abstract
BACKGROUND AND AIMS: The five-year post-resection recurrence rate of hepatocellular carcinoma (HCC) remains 50-70%, and satellite nodules constitute a well-established independent high-risk factor for early recurrence. The therapeutic benefit of adjuvant transarterial chemoembolization (TACE) in this specific subpopulation has not been rigorously evaluated in large cohorts. We therefore aimed to quantify the impact of postoperative adjuvant TACE and to develop a machine learning-based nomogram for individualized survival prediction in HCC patients with pathologically confirmed satellite nodules following radical hepatectomy. METHODS: This retrospective, non-randomized, multi-center cohort enrolled 273 HCC patients with pathologically confirmed satellite nodules who underwent radical hepatectomy between January 2015 and March 2024. Assignment to the adjuvant TACE group versus the radical-resection-only control group was determined by shared decision-making between the treating multidisciplinary team and the patient (or family) at the first postoperative outpatient review, rather than by randomization. Recurrence-free survival (RFS) and overall survival (OS) were compared by Kaplan-Meier analysis with log-rank tests. A 1:1 propensity-score-matched sensitivity analysis (caliper 0.2 SD; covariates: sex, age, BCLC stage, cirrhosis, HBV infection, ALBI grade, MVI, Edmondson grade, satellite multiplicity, resection type, and surgical margin) was performed to adjust for residual baseline imbalance. Independent prognostic factors were identified by univariable and multivariable Cox proportional hazards regression. A peritumoral delta-radiomics score (peritumoral_delta_radscore), derived from contrast-enhanced CT by three-dimensional volumetric segmentation, was generated. Three machine learning-based Cox models-XGBoost-Cox, Cox-LASSO, and CoxBoost-were constructed and evaluated by time-dependent AUC, decision curve analysis (DCA), calibration, and concordance index (C-index) under ten-fold cross-validation. SHAP (SHapley Additive exPlanations) values were applied to quantify feature contributions, and a clinical nomogram was constructed. RESULTS: Adjuvant TACE markedly improved both RFS and OS. In the full cohort, Median RFS was 18.0 months in the TACE group versus 10.6 months in the control group (log-rank P < 0.001), with 1- and 2-year RFS rates of 72.8% vs. 44.6% and 39.2% vs. 8.8%, respectively. Median OS was 36.5 months in the TACE group versus 19.5 months in controls (log-rank P < 0.001), with a 3-year OS of 53.6% vs. 13.5%. After 1:1 propensity-score matching (n = 248; 124 matched pairs), the survival advantage of adjuvant TACE remained statistically significant for both RFS (median 18.0 vs. 9.8 months; log-rank P < 0.001; 1-year RFS 72.6% vs. 42.7%; 2-year RFS 39.5% vs. 9.7%) and OS (median 36.9 vs. 22.9 months; log-rank P < 0.001; 1-year OS 100% vs. 100%; 3-year OS 54.0% vs. 16.1%). Multivariable Cox analysis identified treatment group, female sex, cirrhosis, BCLC stage, and peritumoral_delta_radscore as independent prognostic factors for both RFS and OS. Among the three machine learning models, XGBoost-Cox achieved the highest predictive performance, with time-dependent AUCs of 0.977/0.987/0.984 (1/3/5-year) in the training set (n = 163, events = 155) and 0.900/0.880/0.900 in the independent test set (n = 110, events = 105), consistently outperforming Cox-LASSO and CoxBoost. SHAP analysis identified treatment assignment, sex, BCLC stage C, and peritumoral_delta_radscore as the four dominant contributors. A 4-variable nomogram integrating these features demonstrated excellent calibration and net clinical benefit for 1-, 3-, and 5-year OS prediction. CONCLUSIONS: Adjuvant TACE might significantly prolong both RFS and OS in HCC patients with satellite nodules after radical hepatectomy. The XGBoost-Cox nomogram provides accurate individualized 1-, 3-, and 5-year survival prediction and may serve as an evidence-based decision-support tool for this high-risk subpopulation. As a retrospective, non-randomized study, the present findings require confirmation by prospective multicenter validation, ideally incorporating a randomized or propensity-score-stratified design to mitigate residual selection bias.
Journal IF-equivalent: 4.2 (OpenAlex 2-year mean citedness, value as of 2026-11-16, retrieved 2026-11-18; not the official Clarivate IF)Reference: Wang Y, Li W, Han C, Cao J, Xu H, Ye Y, et al. Machine learning-augmented Cox regression for evaluating adjuvant transarterial chemoembolization efficacy and predicting survival in hepatocellular carcinoma with satellite nodules following radical hepatectomy. BMC Gastroenterol. 2026 Aug 20;26(1):764. doi:10.1186/s12876-026-05235-0. PMID: 43040233.Checked: Abstract only